Ebvallo

Ebvallo is a medicine used to treat adults and children from 2 years of age who, after receiving an organ- or a bone marrow-transplantation, develop a blood cancer called Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). EBV+ PTLD is a potentially fatal complication that can occur after transplantation. Following a transplant, patients receive medicines that weaken their immune system (the body's natural defences) to prevent rejection of the transplant. However, their weakened immune system makes these patients vulnerable to infection with viruses such as the Epstein-Barr virus. In patients with EBV+ PTLD, the Epstein-Barr virus infects white blood cells called B cells after transplantation, causing changes to these cells that can lead to cancer. Ebvallo is used in patients who have received at least one previous treatment, when the disease comes back (relapsed) or when the treatment does not work (refractory). PTLD is rare, and Ebvallo was designated as an ‘orphan medicine’ (a medicine used in rare diseases) on 21 March 2016. Further information on the orphan designation can be found here [EU/3/16/1627](/en/medicines/human/orphan-designations/eu-3-16-1627) Ebvallo contains the active substance tabelecleucel.